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Abstract
Background. Pancreatic cancer is the fifth leading cause of cancer-related deaths in the world. Operative resection is the only
therapeutic option with curative potential for this disease. Objective. The aim of the present study was to correlate clinical
and pathologic parameters with survival in patients submitted to pancreatic resection for pancreatic adenocarcinoma.
Methods. Surgical resection with curative intent (R0 and R1 resections) was performed in 65 pancreatic cancer patients
between 1990 and 2006. The overall results of surgical treatment were retrospectively analyzed and compared with the
clinicopathologic features of these patients. Results. Pylorus-preserving pancreatoduodenectomy was performed in 37
patients (56.9%), classic resection in 35.4%, distal pancreatectomy in 4.6% and total pancreatectomy in 3.6%. The
inhospital mortality was 5% (three patients). Postoperative complications occurred in 28 patients (43%). Mean survival and
five-year survival rate after curative resection were 27 months and 9.0%, respectively. Sex, TNM stage, tumor
differentiation, neural invasion, tumor size and involvement of resection margin were significant prognostic factors on
univariate analysis. Multivariate analysis showed tumor differentiation and neural invasion as prognostic factors. Conclusion.
Patients with pancreatic cancer, even those with poor prognostic factors should be given the opportunity of surgical
resection with curative intent.
Key Words: adenocarcinoma; survival; prognosis; surgery; surgical pathology; pancreatoduodenectomy;
pancreatectomy; pancreatic neoplasms
Introduction
Pancreatic cancer is one of the most fatal malignant
diseases and ranks fifth in cancer mortality worldwide.
Survival after resection remains disappointing, with
five-year survival rates ranging from 10 to 29% [13].
Advances in operative techniques and in perioperative
care have increased the resecability of pancreatic
cancer, and have decreased rates of operative morbid-
ity and mortality [47]. Despite these improvements
long-term outcomes still remain disappointing be-
cause early recurrence still represents the main
challenge for surgeons dealing with pancreatic cancer
patients. Although some reports show five-year survi-
val rates of 2530% [1,811] in the great majority of
the reported series patient survival for more than five
years is rare [1216].
The incidence of pancreatic cancer in the USA
approaches 32,000 cases each year [16,17]. And less
than half of patients in the USA with Stage 1 disease
are offered resection because of the persisting percep-
tion that resection is not worthwhile [18]. In Brazil,
4% of cancer-related deaths are due to pancreatic
cancer and the incidence is about six cases per
100,000 habitants [19].
Objective
The aim of the present study is to correlate
clinical and pathologic findings with survival after
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attempted curative resection for pancreatic adenocar-
cinoma.
Materials and methods
In the period between January of 1990 and Decem-
ber of 2006, 336 patients with pancreatic adenocar-
cinoma were admitted at the Pancreatobiliary
Surgical Unit of the Sa˜o Paulo University Medical
School Hospital. From this patient population 65
were submitted to surgical treatment with curative
intention. The retrospective review of the medical
records of these patients consists the basis of the
present report. Patients with neuroendocrine and
cystic pancreatic neoplasms, and those undergoing
R2 resections were excluded. Patient demographics,
clinical presentation and findings, and pathologic
factors were evaluated to determine the prognostic
factors after resection. Variables studied included:
sex, age, portal vein resection, blood transfusion,
type of pancreatic resection (Whipple, pylorus-
preserving pancreatoduodenectomy, distal pancrea-
tectomy, DP and total pancreatectomy, TP), post-
operative complications (bleeding, pancreatic fistula
and infection) [2022], tumor size, tumor differen-
tiation, lymph node status, neural invasion, margin
status and Tumor, Nodal status and Metastasis
(TNM) staging (according to UICC-2002) [23].
Neoplasms were classified microscopically as well,
moderate, or poorly differentiated tumors according
to Kloppel [23].
Statistical analysis
Continuos variables were compared using either the
two-sample t test or the Wilcox rank sum test
depending on normally or non-normally distributed
data, respectively. Nominal variables were compared
using either the x2 test or the Fisher’s exact test. All
calculated p values were two-sided and p value of less
than or equal to 0.05 was considered statistically
significant. Cumulative survival data were calculated
using the KaplanMeier method. Cox regression
model was used to calculate multivariate analysis
and variables with significance at univariate model
were included.
Results
Patient demographics, clinical factors
Sixty-five patients with the diagnosis of pancreatic
ductal adenocarcinoma underwent R0 or R1 resec-
tions. There were 37 females (57%) and 28 males
(43%) with a mean age of 58 years (range 3985
years). Weight loss was present in 79%, jaundice in
82.4% and nausea or vomiting in 25.4%. Thirty-eight
percent of patients had new-onset diabetes mellitus.
Race, age, weight loss, symptoms of upper Gastro-
intestinal (GI) obstruction, diabetes, jaundice, Carci-
noembryonic Antigen (CEA), Carbohydrate Antigen
19-9 (CA 19-9) levels were not identified as prog-
nostic factors after resection for pancreatic cancer.
Sex was the only parameter that showed statistical
significance on univariate analysis (pB0.05) (Table I).
Table I. Demographic and pre-operative data.
Variable n
Median
survival (mo) P
Race 0.28
White 43 26.3
Black 12 17.8
Oriental 7 32.5
Age (years) 0.55
B60 36 24.5
60 26 29.2
Sex 0.008
Male 26 18.2
Female 36 33.0
Weight loss 0.46
No 13 28.9
Yes 47 26.6
Upper GI obstruction symptoms 0.19
No 46 28.2
Yes 15 19.9
Diabetes 0.67
No 36 25.5
Yes 24 26.3
Jaundice (TB3 mg/dl) 0.56
No 21 30.5
Yes 39 24.2
CEA (5 ug/ml) 0.25
No 20 24.8
Yes 13 41.5
CA 199 (200 ng/ml) 0.09
No 22 33.2
Yes 19 19.8
80,060,040,020,00,0
Survival (mo)
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Figure 1. Overall cumulative survival of patients with pancreatic
adenocarcinoma submitted to surgical resection.
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Operative procedures
Types of pancreatic resection were: pylorus-preser-
ving pancreatoduodenectomy (PPPD) 37 (57%),
classic Whipple (PD) 23 (35%), DP 3 (5%) and TP
2 (3%). Portal vein (PV) resection was performed on
10 patients (15%) in order to obtain an R0 resection.
Mean operative time was 600 minutes. Intra-operative
blood transfusion was needed in 32 patients (49%),
with a median of two units. Pancreatic and bilioen-
teric anastomosis were externally drained through two
separate abdominal stab incisions.
Morbidity and mortality
Postoperative complications occurred in 28 patients
(43%), delayed gastric emptying (DGE) (33%) (16
Grade A, five Grade B and one Grade C) being the
most common, followed by, pancreatic fistula (all
Grade A) (25%), bleeding (12%) and infection (11%)
[21,22,24]. Four patients (6%) were re-operated
because of bleeding (one Grade C and three Grade
B) [21], three (one Grade C and two Grade B) of
whom died because of systemic complications (in-
hospital mortality of 5%). The median duration stay
postoperatively was 15 days (range 746 days).
Prognostic factors
Overall cumulative survival is shown in Figure 1
and the five years survival rate was 9%. The type
of pancreatic resection, amount of intra-operative
bleeding, need for blood transfusion, DGE and
the occurrence of postoperative complications did
not correlate with the long-term survival. Patients
Table II. Surgical and peri-operative data.
Variable n
Mean survival
9SEM (mo) P
Type of pancreatectomy 0.89
PD 22 28.9 (3.9)
PPPD 35 24.2 (3.2)
Distal 3
Total 2
Intra-operative blood transfusion 0.81
No 28 26.5 (3.9)
Yes 32 26.8 (3.7)
Portal vein resection 0.004
No 52 29.4 (3.2)
Yes 10 13.8 (3.8)
PO complicationa 0.11
No 35 23.4 (4.0)
Yes 25 29.5 (3.2)
Pancreatic fistulaa 0.96
No 45 27.6 (3.3)
Yes 14 24.7 (4.5)
Delayed gastric emptyinga 0.29
No 47 25.7 (3.3)
Yes 12 29.6 (4.6)
Infection 0.49
No 53 26.3 (3.2)
Yes 7 34.4 (6.6)
Bleeding 0.61
No 55 28.1 (3.3)
Yes 5 23.2 (7.3)
aData not available for all patients.
Table III. Pathological data.
Variable n Median survival9SEM (mo) P
Tumor size (3 cm) 0.04
No 34 29.9 (3.0)
Yes 28 21.0 (4.3)
N stage 0.09
0 27 30.0 (4.1)
1 35 22.9 (3.0)
TNM 0.05
1a 58 31.3 (10.3)
1b 13 37.6 (6.2)
2a 34 23.0 (4.4)
2b 2 23.3 (3.1)
3 10.5 (00)
Tumor differentiation 0.001
Well 16 25.6 (4.2)
Moderate 44 27.8 (3.4)
Poor 2 6.8 (3.0)
Neural invasion 0.026
No 10 39.6 (5.5)
Yes 52 23.7 (2.8)
Vascular invasion 0.15
No 37 28.7 (3.3)
Yes 25 22.2 (3.7)
Peri-pancreatic invasion 0.023
No 51 26.6 (3.3)
Yes 11 15.2 (2.6)
Tumor margin status 0.006
R0 43 31.6 (3.8)
R1 19 17.1 (2.5)
80,060,040,020,00,0
Survival (mo)
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Figure 2. Cumulative survival according to TNM stages on
univariate analysis.
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submitted to PV resection had lesser survival than
patients whose PV was not resected (14 vs. 29
months) (pB0.025) (Table II). Mean tumor size
was 3.3 cm and most of them had moderate differ-
entiation (68%). Vascular and neural invasion were
present in 38 and 85%, respectively. A positive
histologic margin (R1) was present in 20 patients
(31%). Five (8%) patients were Stage IA, nine (14%)
Stage IB, 13 (20%) Stage IIA, 36 (55%) Stage IIB
and three (3%) Stage III. Mean follow-up and
survival times were 21 and 27 months, respectively.
Poorly differentiated tumors or those with neural
invasion or a positive margin status also had lower
survival rates (pB0.03 each).
Lymph node metastasis and vascular invasion did
not correlate with prolonged survival. In contrast,
TNM stage, neural invasion, tumor differentiation,
peri-pancreatic invasion, tumor size (3 cm) and
resection margin involvement all correlated with
survival (pB0.05) (Table III) (Figures 29). On
multivariate analysis, neural invasion and tumoral
differentiation were significant (pB0.05) (Table IV).
Discussion
In the early 1970s, pancreatoduodenectomy was not
consistently performed for the management of pan-
creatic cancer, because according to some studies its
results were similar to or even worse than bypass
procedures [25,26]. Nowadays, however, pancreato-
duodenectomy can be performed in specialized cen-
ters for the surgical treatment of periampullary
malignancies with a low operative mortality and
morbidity [7,15,27,28]. Many studies have demon-
strated that this improvement was related to the
concentration of this operation in high volume
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Figure 3. Cumulative survival related to tumoral differentiation 
univariate analysis.
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Figure 4. Cumulative survival related to gender  univariate
analysis.
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Figure 5. Cumulative survival related to margin status  univariate
analysis.
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Figure 6. Cumulative survival related to perineural invasion on
univariate analysis.
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centers, specialized in pancreatic surgery [7,29].
Furthermore, technical advances in operative techni-
que and alternative methods for reconstruction of the
alimentary tract after pancreatoduodenectomy [30
34] also contributed for these achievements and
appear to be responsible for the good early results
obtained in the present study. However, these im-
provements do not necessarily correlate with long-
term postoperative survival [15,35], probably due to
the heterogeneity of the clinicopathologic character-
istics of pancreatic cancer [36,37]. This diversity was
also found in the present study and possibly counted
for the poorer prognosis observed in male patients as
there were more women than men with Stage I
disease.
Although PV resection was undertaken in this series
as an attempt to achieve an R0 resection, 31% of
patients still had a positive surgical margin (R1
resection) despite the presumption of a ‘‘curative
resection’’. The finding of a worse prognosis in
patients submitted to PV resection may be also
attributed to the fact that these patients also presented
with larger tumor sizes (pB0.05).
The present study demonstrated similar rates of R0
resection, lymph node involvement and status of
surgical margin for both PPPD and PD procedures,
in accordance with published randomized, controlled
trials [3841].
Although lymph node metastasis, poorly differen-
tiated tumors and positive margins have been asso-
ciated with a worse prognosis in some studies,
[8,42,43], a few patients presenting some of these
poor prognostic factors may live longer than expected
[15,35], whereas other patients without bad prognos-
tic factors will die early. In the present series, poorly
differentiated tumors, neural invasion and the pre-
sence of positive resection margins were associated
with a poor long-term outcome. In contrast, absence
of lymph node metastasis was not a significant
predictor of long-term survival. Schwarz and Smith
demonstrated that an adequate assessment of lymph
node involvement in pancreatic cancer depends on the
number of nodes evaluated, what sometimes can
occur when the surgeon dealing with this disease is
not used to perform a reasonable amount of pancrea-
ticoduodenectomies per year [44]. The small number
of retrieved lymph nodes and the variability of
sampling in the present series may account for the
lack of correlation observed between lymph node
involvement and survival. Furthermore, occult tumor
cells may be found in apparently tumor-free lymph
nodes of pancreatic cancer patients and often over-
looked in conventional histopathology [45]. These
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Figure 7. Cumulative survival related to portal vein resection on
univariate analysis.
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Figure 8. Cumulative survival related to tumor size on univariate
analysis.
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Figure 9. Cumulative survival related to peri-pancreatic tissue
invasion on univariate analysis.
Table IV. Significant variables  multivariate analysis.
Variable P
Neural invasion 0.03
Tumor differentiation 0.04
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micrometastases can, thus, impair prognosis, making
it comparable to that of patients with true lymphatic
metastases [46]. Better methods such as molecular
classification may improve patient selection and
though stratifying the risk of occult metastatic disease.
Current studies of our service are underway to
evaluate the pathological specimen of this patients
population looking for molecular markers (VEGF
receptors, COX2, D2-40).
Long-term survival after pancreatoduodenectomy
for pancreatic carcinoma is far from excellent. The
five-year survival rate nears 10% and patients surviv-
ing more than five years are exceptional [15,35,47].
The actual five-year survival rate of 9% reported
herein is in accordance of other reports that could not
show an improvement in long-term survival after
operative resection of pancreatic cancer [3,35,47].
The results of the present study corroborates with
the findings of other reports which point to the fact
that surgical resection is the only hope for cure of
patients with pancreatic cancer and, thus, this mod-
ality of treatment, followed by an effective adjuvant
therapy, should always be offered to these patients.
References
[1] Trede M, Schwall G, Saeger HD. Survival after pancreato-
duodenectomy. 118 Consecutive resections without an opera-
tive mortality. Ann Surg 1990;/211(4):/44758.
[2] Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA,
Talamini MA, et al. Six hundred fifty consecutive pancreati-
coduodenectomies in the 1990s: pathology, complications,
and outcomes. Ann Surg 1997;226(3):24857; discussion
25760.
[3] Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term
survival after resection for ductal adenocarcinoma of the
pancreas. Is it really improving? Ann Surg 1995;/221(1):/5966.
[4] Baumel H, Huguier M, Manderscheid JC, Fabre JM, Houry
S, Fagot H. Results of resection for cancer of the exocrine
pancreas: a study from the French Association of Surgery. Br J
Surg 1994;/81(1):/1027.
[5] Janes RH Jr, Niederhuber JE, Chmiel JS, Winchester DP,
Ocwieja KC, Karnell JH, et al. National patterns of care for
pancreatic cancer. Results of a survey by the commission on
cancer. Ann Surg 1996;/223(3):/26172.
[6] Yeo CJ, Cameron JL. Pancreatic cancer. Curr Probl Surg
1999;/36(2):/59152.
[7] Buchler MW, Wagner M, Schmied BM, Uhl W, Friess H,
Z’Graggen K. Changes in morbidity after pancreatic resection:
toward the end of completion pancreatectomy. Arch Surg
2003;138(12):13104; discussion 1315.
[8] Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH,
Goodman SN, et al. Pancreaticoduodenectomy for cancer of
the head of the pancreas. 201 Patients. Ann Surg 1995;/221(6):/
72131.
[9] Nagakawa T, Nagamori M, Futakami F, Tsukioka Y, Kaya-
hara M, Ohta T, et al. Results of extensive surgery for
pancreatic carcinoma. Cancer 1996;/77(4):/6405.
[10] Tsiotos GG, Farnell MB, Sarr MG. Are the results of
pancreatectomy for pancreatic cancer improving? World J
Surg 1999;/23(9):/9139.
[11] Farnell MB, Nagorney DM, Sarr MG. The Mayo clinic
approach to the surgical treatment of adenocarcinoma of the
pancreas. Surg Clin North Am 2001;/81(3):/61123.
[12] Allema JH, Reinders ME, van Gulik TM, van Leeuwen DJ,
Verbeek PC, de Wit LT, et al. Results of pancreaticoduode-
nectomy for ampullary carcinoma and analysis of prognostic
factors for survival. Surgery 1995;/117(3):/24753.
[13] Trede M, Richter A, Wendl K. Personal observations,
opinions, and approaches to cancer of the pancreas and the
periampullary area. Surg Clin North Am 2001;/81(3):/595
610.
[14] Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler
MW. Curative resection is the single most important factor
determining outcome in patients with pancreatic adenocarci-
noma. Br J Surg 2004;/91(5):/58694.
[15] Han SS, Jang JY, Kim SW, Kim WH, Lee KU, Park YH.
Analysis of long-term survivors after surgical resection for
pancreatic cancer. Pancreas 2006;/32(3):/2715.
[16] Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer
statistics, 2007. CA Cancer J Clin 2007;/57(1):/4366.
[17] Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al.
Cancer statistics, 2006. CA Cancer J Clin 2006;/56(2):/10630.
[18] Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester
DP, Talamonti MS. National failure to operate on early stage
pancreatic cancer. Ann Surg 2007;/246(2):/17380.
[19] Moraes VMD. Evoluca¨o do padra¨o alimentar e tendeˆncia da
mortalidade por caˆncer de paˆncreas nas capitais do Brasil,
19801997/Evolution of feeding behavior trends of the
mortality the pancreatic neoplasms in Brazil states: 1980
1997, in Apresentada a Escola Nacional de Sau´de Pu´blica.
2002: Rio de Janeiro, Brasil. p. 106.
[20] Bassi C, Butturini G, Molinari E, Mascetta G, Salvia R,
Falconi M, et al. Pancreatic fistula rate after pancreatic
resection. The importance of definitions. Dig Surg 2004;/
21(1):/549.
[21] Wente MN, Veit JA, Bassi C, Dervenis C, Fingerhut A,
Gouma DJ, et al. Postpancreatectomy hemorrhage (PPH): an
International Study Group of Pancreatic Surgery (ISGPS)
definition. Surgery 2007;/142(1):/205.
[22] Wente MN, Bassi C, Dervenis C, Fingerhut A, Gouma DJ,
Izbicki JR, et al. Delayed gastric emptying (DGE) after
pancreatic surgery: a suggested definition by the International
Study Group of Pancreatic Surgery (ISGPS). Surgery 2007;/
142(5):/7618.
[23] Kloppel GEA. Ductal adenocarcinoma of the pancreas. In:
Hamilton SR, Aaeltonen LA, editors. World Health Organiza-
tion classification of tumours, pathology of tumours of the
digestive tract. Lyon: IARC Press; 2000. p. 22130.
[24] Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki
J, et al. Postoperative pancreatic fistula: an international study
group (ISGPF) definition. Surgery 2005;/138(1):/813.
[25] Crile G Jr. The advantages of bypass operations over radical
pancreatoduodenectomy in the treatment of pancreatic carci-
noma. Surg Gynecol Obstet 1970;/130(6):/104953.
[26] Shapiro TM. Adenocarcinoma of the pancreas: a statistical
analysis of biliary bypass vs Whipple resection in good risk
patients. Ann Surg 1975;/182(6):/71521.
[27] Neoptolemos JP, Russell RC, Bramhall S, Theis B. Low
mortality following resection for pancreatic and periampullary
tumours in 1026 patients: UK survey of specialist pancreatic
units. UK Pancreatic Cancer Group. Br J Surg 1997;/84(10):/
13706.
[28] Sosa JA, Bowman HM, Gordon TA, Bass EB, Yeo CJ,
Lillemoe KD, et al. Importance of hospital volume in the
overall management of pancreatic cancer. Ann Surg 1998;/
228(3):/42938.
[29] Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand
consecutive pancreaticoduodenectomies. Ann Surg 2006;/
244(1):/105.
[30] Machado MC, da Cunha JE, Bacchella T, Bove P. A modified
technique for the reconstruction of the alimentary tract after
pancreatoduodenectomy. Surg Gynecol Obstet 1976;/143(2):/
2712.
Prognostic factor in pancreatic cancer 361
[31] Traverso LW, Longmire WP Jr. Preservation of the pylorus in
pancreaticoduodenectomy. Surg Gynecol Obstet 1978;/146(6):/
95962.
[32] Machado MC, Figueira ER, Machado MA, Jukemura J,
Cunha JE, Perini MV, et al. Portal vein resection: a modified
technique for reconstruction after pancreaticoduodenectomy.
J Surg Oncol 2004;/88(1):/524.
[33] Varty PP, Yamamoto H, Farges O, Belghiti J, Sauvanet A.
Early retropancreatic dissection during pancreaticoduodenect-
omy. Am J Surg 2005;/189(4):/48891.
[34] Jain S, Sacchi M, Vrachnos P, Lygidakis NJ. Carcinoma of the
pancreas with portal vein involvement  our experience with a
modified technique of resection. Hepatogastroenterology
2005;/52(65):/1596600.
[35] Cooperman AM. Pancreatic cancer: the bigger picture. Surg
Clin North Am 2001;/81(3):/55774.
[36] Youmans R, McGee JM, Lee J, Malnar K, Bellefeuille C,
Berry B. Surgical treatment of cancer of the pancreas in large
community hospitals. J Okla State Med Assoc 1996;/89(1):/16
21.
[37] Takai S, Satoi S, Toyokawa H, Yanagimoto H, Sugimoto N,
Tsuji K, et al. Clinicopathologic evaluation after resection for
ductal adenocarcinoma of the pancreas: a retrospective, single-
institution experience. Pancreas 2003;/26(3):/2439.
[38] Lin PW, Lin YJ. Prospective randomized comparison between
pylorus-preserving and standard pancreaticoduodenectomy.
Br J Surg 1999;/86(5):/6037.
[39] Seiler CA, Wagner M, Sadowski C, Kulli C, Buchler MW.
Randomized prospective trial of pylorus-preserving vs. Classic
duodenopancreatectomy (Whipple procedure): initial clinical
results. J Gastrointest Surg 2000;/4(5):/44352.
[40] Tran KT, Smeenk HG, van Eijck CH, Kazemier G, Hop WC,
Greve JW, et al. Pylorus preserving pancreaticoduodenectomy
versus standard Whipple procedure: a prospective, rando-
mized, multicenter analysis of 170 patients with pancreatic
and periampullary tumors. Ann Surg 2004;/240(5):/73845.
[41] Lin PW, Shan YS, Lin YJ, Hung CJ. Pancreaticoduodenect-
omy for pancreatic head cancer: PPPD versus Whipple
procedure. Hepatogastroenterology 2005;/52(65):/16014.
[42] Allison DC, Piantadosi S, Hruban RH, Dooley WC, Fishman
EK, Yeo CJ, et al. DNA content and other factors associated
with ten-year survival after resection of pancreatic carcinoma.
J Surg Oncol 1998;/67(3):/1519.
[43] Cleary SP, Gryfe R, Guindi M, Greig P, Smith L, Mackenzie
R, et al. Prognostic factors in resected pancreatic adenocarci-
noma: analysis of actual 5-year survivors. J Am Coll Surg
2004;/198(5):/72231.
[44] Schwarz RE, Smith DD. Extent of lymph node retrieval and
pancreatic cancer survival: information from a large US
population database. Ann Surg Oncol 2006;/13(9):/1189200.
[45] Milsmann C, Fuzesi L, Werner C, Becker H, Horstmann O.
Significance of occult lymphatic tumor spread in pancreatic
cancer]. Chirurg 2005;/76(11):/106472.
[46] Demeure MJ, Doffek KM, Komorowski RA, Wilson SD.
Adenocarcinoma of the pancreas: detection of occult metas-
tases in regional lymph nodes by a polymerase chain reaction-
based assay. Cancer 1998;/83(7):/132834.
[47] Mosca F, Giulianotti PC, Balestracci T, Di Candio G,
Pietrabissa A, Sbrana F, et al. Long-term survival in pancreatic
cancer: pylorus-preserving versus Whipple pancreatoduode-
nectomy. Surgery 1997;/122(3):/55366.
362 M.V. Perini et al.
